•  
  •  
  •  
  •  

2025-08-29 02:45:11

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
  • HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
  • Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
  • SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
  • Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd

Keywords Selected:  ExtendedReleaseTablets

Stock Report

  • Alembic Pharmaceuticals announces USFDA Final Approval for Paliperidone Extended Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg
  • Lupin Launches Mirabegron Extended-Release Tablets in the United States
  • Zydus launches Mirabegron Extended-Release Tablets in the US
  • Lupin launches Mirabegron Extended-Release Tablets in the United States
  • Zydus receives Final Approval from the USFDA for Isosorbide Mononitrate Extended-Release, Tablets USP, 30 mg, 60 mg, and 120 mg
  • Lupin receives approval from U.S. FDA for Metoprolol Succinate Extended-Release Tablets USP
  • Dr. Reddy's Laboratories announces its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
  • Zydus receives final approval from the USFDA for Minocycline Hydrochloride Extended-Release Tablets USP, 55 mg, 65 mg, and 115 mg
  • Unichem Laboratories Ltd receives ANDA approval for Ranolazine Extended-Release Tablets
  • Lupin receives approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets
  • JB Chemicals & Pharmaceuticals Ltd receives ANDA approval for Venlafaxine Hydrochloride Extended-Release Tablets from USFDA
  • Alembic Pharmaceuticals receives USFDA Final Approval for Nifedipine Extended-Release Tablets USP, 30 mg, 60 mg and 90 mg
  • Zydus receives final approval from USFDA and 180 days shared exclusivity for Mirabegron Extended-Release Tablets
  • Lupin receives approval from U.S. FDA for Mirabegron Extended-Release Tablets
  • Zydus receives two final approvals from the USFDA for Venlafaxine Extended-Release Tablets and Pregabalin Extended-Release Tablets
  • Lupin launches Desvenlafaxine Extended-Release Tablets in the United States
  • Unichem Laboratories receives ANDA Approval for Quetiapine Extended-Release Tablets
  • Dr. Reddy's Labs launches Fesoterodine Fumarate Extended-Release Tablets in the U.S. market
  • Lupin receives approval from U.S. FDA for Paliperidone Extended-Release Tablets
  • Unichem Laboratories ANDA approval for Divalproex Sodium Extended-Release Tablets

Latest Post

  • Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
  • HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
  • Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
  • SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
  • Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024